Alexis Noel Cox-Holmes

Mrs. Alexis Noel Cox-Holmes

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 October 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
George B.H. GreenGeorge B.H. Green
George B.H. Green
ACAlexis Noel Cox-Holmes
Alexis Noel Cox-Holmes
APAnna Claire Potier
Anna Claire Potier
GMGillian H. Marlow
Gillian H. Marlow
BMBraden C McFarland
Braden C McFarland
Studies increasingly support the role of the gut microbiota in glioma development and treatment, although the exact mechanisms remain unclear. Research indicates that the gut microbiota can influence glioma progression, response to therapies, and the effectiveness of treatments like immunotherapy, with certain microbial compositions being linked to better outcomes. Additionally, the gut microbiota impacts the tumor microenvironment, affecting both tumor growth and the response to treatment. This review will explore glioma, the gut microbiota, and how their interaction shapes glioma development and therapy responses. Additionally, this review examines the influence of gut microbiota metabolites, such as short-chain fatty acids (SCFAs) and tryptophan, on glioma development and treatment. It also explores gut microbiome signaling via pattern recognition receptors, and the role of molecular mimicry between microbial and tumor antigens in glioblastoma, and if these interactions affect glioma development and treatment.

17 May 2024 in Microorganisms
Verified
Journal Article
Open access
PDF file
George B.H. GreenGeorge B.H. Green
George B.H. Green
ACAlexis Noel Cox-Holmes
Alexis Noel Cox-Holmes
OBOlivia Backan
Olivia Backan
OVOlivia B Valbak
Olivia B Valbak
APAnna Claire Potier
Anna Claire Potier
BMBraden C McFarland
Braden C McFarland
Along with the standard therapies for glioblastoma, patients are commonly prescribed trimethoprim-sulfamethoxazole (TMP-SMX) and dexamethasone for preventing infections and reducing cerebral edema, respectively. Because the gut microbiota impacts the efficacy of cancer therapies, it is important to understand how these medications impact the gut microbiota of patients. Using mice that have been colonized with human microbiota, this study sought to examine how TMP-SMX and dexamethasone affect the gut microbiome. Two lines of humanized microbiota (HuM) Rag1−/− mice, HuM1Rag and HuM2Rag, were treated with either TMP-SMX or dexamethasone via oral gavage once a day for a week. Fecal samples were collected pre-treatment (pre-txt), one week after treatment initiation (1 wk post txt), and three weeks post-treatment (3 wk post txt), and bacterial DNA was analyzed using 16S rRNA-sequencing. The HuM1Rag mice treated with TMP-SMX had significant shifts in alpha diversity, beta diversity, and functional pathways at all time points, whereas in the HuM2Rag mice, it resulted in minimal changes in the microbiome. Likewise, dexamethasone treatment resulted in significant changes in the microbiome of the HuM1Rag mice, whereas the microbiome of the HuM2Rag mice was mostly unaffected. The results of our study show that routine medications used during glioblastoma treatment can perturb gut microbiota, with some microbiome compositions being more sensitive than others, and these treatments could potentially affect the overall efficacy of standard-of-care therapy.

30 October 2024 in Pharmacology Biochemistry and Behavior
Verified
Journal Article
Open access
MCMartina Krakora Compagno
Martina Krakora Compagno
CSClaudia Rose Silver
Claudia Rose Silver
ACAlexis Noel Cox-Holmes
Alexis Noel Cox-Holmes
KBKari Basso
Kari Basso
CBCaroline Bishop
Caroline Bishop
DFDebra Fadool
Debra Fadool
The consequences of perinatal cannabidiol (CBD) exposure are severely understudied, but are important, given its widespread use and believed safety as a natural supplement. The objective of this study was to test the health, metabolic, and behavioral consequences of perinatal CBD exposure on dams and their offspring raised to adult. Primiparous female C57BL/6J mice were orally administered 100 mg/kg CBD in strawberry jam to expose offspring during gestation, lactation, or both using a cross-fostering design. Adult offspring were metabolically profiled using indirect calorimetry and intraperitoneal glucose tolerance testing. Adults were behaviorally phenotyped, video recorded, and mouse position tracked using DeepLabCut. CBD was detected in maternal plasma using LC-MS 10-min post consumption (34.2 ± 1.7 ng/μl) and peaked within 30 min (371.0 ± 34.0 ng/μl). Fetal exposure to CBD significantly decreased survival of the pups, and decreased male postnatal development, but did not alter litter size, maternal body weight or pup birth weight. We observed many sex-dependent effects of perinatal CBD exposure. Exposure to CBD during gestation and lactation increased meal size, caloric intake, and respiratory exchange ratio for adult male offspring, while exposure during lactation decreased fasting glucose, but had no effect on clearance. Adult female offspring exposed to CBD during lactation showed increased drink size. Perinatal CBD exposure increased obsessive compulsive- and decreased anxiety-like behaviors (marble burying, light-dark box, elevated-plus maze) in female mice, decreased long-term object memory in male mice, and had no effect on attention tasks for either sex. We conclude that orally-administered CBD during pregnancy affects behavior and metabolism in a sex-dependent manner, and mice are differentially sensitive to exposure during gestation vs. lactation, or both. Because long-term changes are observed following perinatal exposure to the drug, and exposure significantly decreases survival to weaning, more research during development is warranted.

12 July 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
MCMartina Krakora Compagno
Martina Krakora Compagno
CSClaudia Rose Silver
Claudia Rose Silver
ACAlexis Noel Cox-Holmes
Alexis Noel Cox-Holmes
KBKari Basso
Kari Basso
CBCaroline Bishop
Caroline Bishop
DFDebra Fadool
Debra Fadool
Rationale The consequences of perinatal cannabidiol (CBD) exposure are severely understudied, but are important, given its widespread use and believed safety as a natural supplement. Objective The objective of this study was to test the health, metabolic, and behavioral consequences of perinatal CBD exposure on dams and their offspring raised to adult. Methods Primiparous female C57BL/6J mice were orally administered 100 mg/kg CBD in strawberry jam to expose offspring during gestation, lactation, or both using a cross-fostering design. Adult offspring were metabolically profiled using indirect calorimetry and intraperitoneal glucose tolerance testing. Adults were behaviorally phenotyped, video recorded, and mouse position tracked using DeepLabCut. Results CBD was detected in maternal plasma using LC-MS 10-min post consumption (34.2 ± 1.7 ng/ul) and peaked within 30 min (371.0 ± 34.0 ng/ul). Fetal exposure to CBD significantly decreased survival of the pups, and decreased male postnatal development, but did not alter litter size, maternal body weight or pup birth weight. We observed many sex-dependent effects of perinatal CBD exposure. Exposure to CBD during gestation and lactation increased meal size, caloric intake, and respiratory exchange ratio for adult male offspring, while exposure during lactation decreased fasting glucose, but had no effect on clearance. Adult female offspring exposed to CBD during lactation showed increased drink size. Perinatal CBD exposure increased obsessive compulsive- and decreased anxiety-like behaviors (marble burying, light-dark box, elevated-plus maze) in female mice, decreased long-term object memory in male mice, and had no effect on attention tasks for either sex. Conclusions We conclude that orally-administered CBD during pregnancy affects behavior and metabolism in a sex-dependent manner, and mice are differentially sensitive to exposure during gestation vs. lactation, or both. Because long-term changes are observed following perinatal exposure to the drug, and exposure significantly decreases survival to weaning, more research during development is warranted. HIGHLIGHTS Mice can be trained to orally consume CBD using strawberry jam as the vehicle. CBD administration to pregnant dams decreases pup survival to weaning age without significantly affecting maternal behavior. Perinatal CBD exposure decreases developmental body weight in males. Gestational or lactational CBD increases the respiratory exchange ratio (RER), increases mean meal and drink size, and reduces fasting glucose in a sex-dependent manner. CBD increases obsessive-compulsive like behavior in adult offspring, which could be eliminated in females by cross-fostering to a drug-free dam. Perinatal CBD selectively decreases anxiety-like behavior in females and decreases long-term object memory in males.

19 March 2026 in Nutrients
Verified
Journal Article
Open access
PDF file
George B.H. GreenGeorge B.H. Green
George B.H. Green
ACAlexis Noel Cox-Holmes
Alexis Noel Cox-Holmes
JFJonathan T. Flowers
Jonathan T. Flowers
MWMichael B. Williams
Michael B. Williams
APAnna Claire E. Potier
Anna Claire E. Potier
BMBraden C McFarland
Braden C McFarland
This narrative review aims to explore the relationship between glioma and nutrition throughout stages of treatment and recovery. Gliomas are aggressive brain tumors that significantly impair quality of life and present treatment challenges. There has been a growing interest regarding the gut–brain axis and the microbiome, particularly their roles in modulating immune function and influencing the response to cancer treatment. This review examines how specific nutritional approaches may assist patients throughout the course of chemotherapy, radiation, immunotherapy, surgical intervention, and the recovery process. It also addresses the potential for integrative nutritional approaches to complement conventional treatment and improve clinical outcomes. Emerging evidence suggests that nutrition may influence immune function, treatment-related side effects, and the tumor microenvironment, in part through effects on the gut microbiota. Nutritional support during therapy has been linked to increased strength, decreased inflammation, and improved treatment tolerance. Dietary patterns may influence gut–brain interactions and systemic immune responses, opening the potential to improve therapeutic outcomes in glioma. In summary, nutrition may represent an important supportive component of glioma care, while microbiota-mediated and metabolic dietary strategies remain areas of active investigation. Further clinical studies are needed to determine whether specific nutritional interventions can improve survival, treatment response, or quality of life in patients with glioma.